News & Events
Grants, last few years
NIH/NIDDK Phase II SBIR awarded Sept 2015
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing.
NIH/NIDDK Phase 1 SBIR awarded July 2016
Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem cells.
NIH/NIDDK Phase I SBIR awarded Sept 2016
Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function.
NIH/NIDDK Phase I SBIR awarded Sept 2016
Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications.
WI SBIR Advance awarded 2017
WI SBIR Advance awarded 2017
NIH GRANTS 2022
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells.
Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance